Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Triple-Negative Breast Carcinoma”

71 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 71 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07419880
What this trial is testing

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Who this might be right for
Triple -Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Study completedNCT02834403
What this trial is testing

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Metastatic Triple Negative Breast Cancer
The Methodist Hospital Research Institute 37
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Ended earlyNCT01375023
What this trial is testing

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

Who this might be right for
Breast Cancer
European Institute of Oncology 3
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Early research (Phase 1)Study completedNCT01837602
What this trial is testing

CMet CAR RNA T Cells Targeting Breast Cancer

Who this might be right for
Metastatic Breast CancerTriple Negative Breast Cancer
University of Pennsylvania 6
Testing effectiveness (Phase 2)UnknownNCT02587689
What this trial is testing

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+1 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 20
Testing effectiveness (Phase 2)UnknownNCT02839954
What this trial is testing

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT01677455
What this trial is testing

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast CancerTriple Negative Breast Cancer+1 more
Synta Pharmaceuticals Corp. 51
Early research (Phase 1)Ended earlyNCT02706392
What this trial is testing

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell Carcinoma+10 more
Fred Hutchinson Cancer Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT05749588
What this trial is testing

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Who this might be right for
Triple-negative Breast Cancer
Fudan University 120
Early research (Phase 1)Looking for participantsNCT06586957
What this trial is testing

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc. 150
Testing effectiveness (Phase 2)Study completedNCT03345485
What this trial is testing

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Who this might be right for
Small Cell Lung CancerSoft Tissue SarcomaTriple-negative Breast Cancer+2 more
Mundipharma Research Limited 71
Early research (Phase 1)Study completedNCT03291938
What this trial is testing

IACS-010759 in Advanced Cancers

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+22 more
M.D. Anderson Cancer Center 29
Early research (Phase 1)Study completedNCT01837095
What this trial is testing

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Polyphor Ltd. 54
Early research (Phase 1)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+2 more
Accent Therapeutics 90
Not applicableEnded earlyNCT05891197
What this trial is testing

A Biomarker Screening Protocol for Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung Cancer+19 more
Lyell Immunopharma, Inc. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Load More Results